University of Toronto

Roche Diagnostics Operations, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Ruth Isserlin

Herbert Von Der Eltz

Georg Hess

Dirk Block

Ursula-Henrike Wienhues-Thelen

Andrew Emili

Hendrik Huedig

Peter Liu

Anthony Gramolini

David MacLennan

Vincent Fong

Thomas Kislinger

David Maclennan

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.

Use of IGFBP-7 in the assessment of heart failure

The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.

Use of SLIM-1 in the assessment of heart failure

Growing community of inventors

Thornhill, Canada

Ruth Isserlin